Neuland Laboratories (524558) investor relations material

Executive summary

• Q1 FY27 revenue grew 116.3% year-over-year to INR 650.1 crore, driven by strong commercial CMS project execution, robust GDS contributions, and a favorable business mix.

• EBITDA reached INR 231.1 crore with a margin of 35.5%, and profit after tax was INR 147.4 crore, up 975.0% year-over-year.

• Key products such as eszopiclone, mirtazapine, escitalopram, lansoprazole, Ezetimibe, and Aripiprazole Sterile performed well.

• Strategic investments in R&D, peptides, and capacity expansion, including a new CDMO partnership with Gland Pharma, are positioning the company for long-term growth.

• Customer engagement deepened, focusing on capability-led discussions and long-term partnerships.

Financial highlights

• Total income for Q1 FY27 reached INR 650.1 crore, up 116.3% year-over-year, with consolidated net profit at INR 147.4 crore.

• EBITDA for Q1 FY27 was INR 231.1 crore, a 448.2% increase year-over-year, with a margin of 35.5%.

• Gross margin improved to 61.2% from 55.3% in Q1 FY26, reflecting a favorable product mix.

• Working capital days reduced to 84 in Q1 FY27 from 137 in Q4 FY26, mainly due to lower receivables.

• Capex outflow for Q1 FY27 was INR 121.6 crore, mainly for new R&D and peptide facilities.

Outlook and guidance

• Management expects FY 2027 and FY 2028 to be growth years, targeting around 20% annual growth, with continued investment intensity and a healthy margin profile.

• Development revenues are expected to rise in FY 2027, with new projects—especially in peptides—potentially leading to future commercial launches.

• Manufacturing capacity at Unit 1 will be enhanced by 18 KL, with completion expected in 6-7 months to meet growing demand.

• Strategic partnership with Gland Pharma aims to add 1,400 kg annual sterile API capacity, supporting future growth and supply resilience.